Other compounds

Cardarine: molecular data, studies & sources

Cardarine is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-01 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular record not yet resolved

A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.

MF: not assigned · MW: not assigned · Structure: not assigned

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Cardarine as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

3 registered studies matched.

Study	Phase · status	Conditions	Sponsor · size
A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese SubjectsNCT00388180 · start 2004-12	Not applicableCompleted	Hypercholesterolemia · Dyslipidaemias · Obesity	GlaxoSmithKline71 participants
A Multi-center, Three-staged With Interim Analyses, Parallel, Randomized, Double-blind, fenofibrate-and Placebo-controlled Proof of Concept and Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma High-density Lipoprotein Cholesterol (HDLc) and Triglycerides of Eight Weeks Treatment With GW501516 in Otherwise Healthy Patients With Low HDLc, Mildly to Moderately Elevated Triglycerides, and Normal Low-density Lipoprotein Cholesterol (LDLc)NCT00158899 · start 2004-08 · primary completion 2006-06	Phase 2Completed	Dyslipidaemias · Dyslipidaemia	GlaxoSmithKline424 participants
Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic SyndromeNCT00841217 · start 2003-04 · primary completion 2005-08	Phase 4Completed	Obesity · Lipid Disorders · Cardiovascular Disease	The University of Western Australia13 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

No matching human study was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Preclinical / laboratory research
Comprehensive characterization of the peroxisome proliferator activated receptor-δ agonist GW501516 for horse doping control analysis.
Trevisiol S, Moulard Y, Delcourt V et al. · Drug testing and analysis · 2021
PMID 33547737 · DOI: 10.1002/dta.3013
Preclinical / laboratory research
PPARδ agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.
Santhanam AV, d'Uscio LV, He T et al. · Brain research · 2012
PMID 22982594 · DOI: 10.1016/j.brainres.2012.09.012
Research publication · design requires review
PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis.
Ji Y, Li H, Wang F et al. · Frontiers in pharmacology · 2018
PMID 30002625 · DOI: 10.3389/fphar.2018.00648
Research publication · design requires review
Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells.
Smith RW, Coleman JD, Thompson JT et al. · Biochemistry and biophysics reports · 2016
PMID 28955982 · DOI: 10.1016/j.bbrep.2016.10.014
Research publication · design requires review
Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS.
Kintz P, Ameline A, Gheddar L et al. · Drug testing and analysis · 2020
PMID 32298044 · DOI: 10.1002/dta.2802
Preclinical / laboratory research
Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.
Defaux A, Zurich MG, Braissant O et al. · Journal of neuroinflammation · 2009
PMID 19422681 · DOI: 10.1186/1742-2094-6-15
Preclinical / laboratory research
PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle.
Terada S, Wicke S, Holloszy JO et al. · American journal of physiology. Endocrinology and metabolism · 2005
PMID 16278250 · DOI: 10.1152/ajpendo.00430.2005
Research publication · design requires review
Novel Solid Forms of Cardarine/GW501516 and Their Characterization by X-Ray Diffraction, Thermal, Computational, FTIR, and UV Analysis.
Turza A, Bosca M, Muresan-Pop M et al. · Pharmaceutics · 2025
PMID 40006519 · DOI: 10.3390/pharmaceutics17020152

Cardarine supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.